High-throughput virtual laboratory for drug discovery using massive datasets

被引:29
|
作者
Glaser, Jens [1 ]
Vermaas, Josh V. [1 ]
Rogers, David M. [1 ]
Larkin, Jeff [2 ]
LeGrand, Scott [2 ]
Boehm, Swen [3 ]
Baker, Matthew B. [3 ]
Scheinberg, Aaron [4 ]
Tillack, Andreas F. [5 ]
Thavappiragasam, Mathialakan [6 ]
Sedova, Ada [6 ]
Hernandez, Oscar [3 ]
机构
[1] Oak Ridge Natl Lab, Natl Ctr Computat Sci, Oak Ridge, TN 37831 USA
[2] NVIDIA Corp, Santa Clara, CA USA
[3] Oak Ridge Natl Lab, Comp Sci & Math Div, Oak Ridge, TN 37831 USA
[4] Jubilee Dev, Cambridge, MA USA
[5] Scripps Res, San Diego, CA USA
[6] Oak Ridge Natl Lab, Biosci Div, Oak Ridge, TN 37831 USA
关键词
High-throughput virtual screening; drug discovery; GPU acceleration; high-performance database query; MOLECULAR DOCKING; RATIONAL DESIGN; INHIBITORS; ACCURATE;
D O I
10.1177/10943420211001565
中图分类号
TP3 [计算技术、计算机技术];
学科分类号
0812 ;
摘要
Time-to-solution for structure-based screening of massive chemical databases for COVID-19 drug discovery has been decreased by an order of magnitude, and a virtual laboratory has been deployed at scale on up to 27,612 GPUs on the Summit supercomputer, allowing an average molecular docking of 19,028 compounds per second. Over one billion compounds were docked to two SARS-CoV-2 protein structures with full optimization of ligand position and 20 poses per docking, each in under 24 hours. GPU acceleration and high-throughput optimizations of the docking program produced 350x mean speedup over the CPU version (50x speedup per node). GPU acceleration of both feature calculation for machine-learning based scoring and distributed database queries reduced processing of the 2.4 TB output by orders of magnitude. The resulting 50x speedup for the full pipeline reduces an initial 43 day runtime to 21 hours per protein for providing high-scoring compounds to experimental collaborators for validation assays.
引用
收藏
页码:452 / 468
页数:17
相关论文
共 50 条
  • [1] High-throughput virtual screening for drug discovery in parallel
    Toledo-Sherman, LM
    Chen, DQ
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2002, 5 (03) : 414 - 421
  • [2] High-throughput and in silico screenings in drug discovery
    Phatak, Sharangdhar S.
    Stephan, Clifford C.
    Cavasotto, Claudio N.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (09) : 947 - 959
  • [3] High-throughput kinetics in drug discovery
    Pinto, Maria Filipa
    Sirina, Julija
    Holliday, Nicholas D.
    Mcwhirter, Claire L.
    SLAS DISCOVERY, 2024, 29 (05)
  • [4] A High-Throughput Screen for Antibiotic Drug Discovery
    Scanlon, Thomas C.
    Dostal, Sarah M.
    Griswold, Karl E.
    BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (02) : 232 - 243
  • [5] High-throughput screening, metabolomics and drug discovery
    Harrigan, GG
    Yates, LA
    IDRUGS, 2006, 9 (03) : 188 - 192
  • [6] Data processing for high-throughput mass spectrometry in drug discovery
    Liu, Chang
    Zhang, Hui
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (07) : 815 - 825
  • [7] Modern analytical approaches to high-throughput drug discovery
    Gomez-Hens, A.
    Aguilar-Caballos, M. P.
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2007, 26 (03) : 171 - 182
  • [8] Advances in high-throughput mass spectrometry in drug discovery
    Duenas, Maria Emilia
    Peltier-Heap, Rachel E.
    Leveridge, Melanie
    Annan, Roland S.
    Buttner, Frank H.
    Trost, Matthias
    EMBO MOLECULAR MEDICINE, 2023, 15 (01)
  • [9] High-throughput drug screens for amyotrophic lateral sclerosis drug discovery
    McGown, Alexander
    Stopford, Matthew John
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (11) : 1015 - 1025
  • [10] MyoScreen, a High-Throughput Phenotypic Screening Platform Enabling Muscle Drug Discovery
    Young, Joanne
    Margaron, Yoran
    Fernandes, Mathieu
    Duchemin-Pelletier, Eve
    Michaud, Joris
    Flaender, Melanie
    Lorintiu, Oana
    Degot, Sebastien
    Poydenot, Pauline
    SLAS DISCOVERY, 2018, 23 (08) : 790 - 806